These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32115845)

  • 41. Matching-adjusted indirect comparisons: Application to time-to-event data.
    Aouni J; Gaudel-Dedieu N; Sebastien B
    Stat Med; 2021 Feb; 40(3):566-577. PubMed ID: 33111986
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Acceptance of Indirect Treatment Comparison Methods in Oncology by Health Technology Assessment Agencies in England, France, Germany, Italy, and Spain.
    Macabeo B; Rotrou T; Millier A; François C; Laramée P
    Pharmacoecon Open; 2024 Jan; 8(1):5-18. PubMed ID: 38097828
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
    Wade R; Grosso A; South E; Rothery C; Saramago P; Schmitt L; Wright K; Palmer S
    Pharmacoeconomics; 2019 Feb; 37(2):131-139. PubMed ID: 30112635
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Indirect comparisons of competing interventions.
    Glenny AM; Altman DG; Song F; Sakarovitch C; Deeks JJ; D'Amico R; Bradburn M; Eastwood AJ;
    Health Technol Assess; 2005 Jul; 9(26):1-134, iii-iv. PubMed ID: 16014203
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
    Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effectiveness of two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of moderately severe scalp psoriasis: a systematic review of direct and indirect evidence.
    Bottomley JM; Taylor RS; Ryttov J
    Curr Med Res Opin; 2011 Jan; 27(1):251-68. PubMed ID: 21142838
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multilevel network meta-regression for population-adjusted treatment comparisons.
    Phillippo DM; Dias S; Ades AE; Belger M; Brnabic A; Schacht A; Saure D; Kadziola Z; Welton NJ
    J R Stat Soc Ser A Stat Soc; 2020 Jun; 183(3):1189-1210. PubMed ID: 32684669
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
    Kirson NY; Rao S; Birnbaum HG; Kantor E; Wei RS; Cifaldi M
    J Med Econ; 2013; 16(4):479-89. PubMed ID: 23339434
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
    Sawyer LM; Cornic L; Levin LÅ; Gibbons C; Møller AH; Jemec GB
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):355-366. PubMed ID: 30289198
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2.
    Hoaglin DC; Hawkins N; Jansen JP; Scott DA; Itzler R; Cappelleri JC; Boersma C; Thompson D; Larholt KM; Diaz M; Barrett A
    Value Health; 2011 Jun; 14(4):429-37. PubMed ID: 21669367
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.
    Jansen JP; Fleurence R; Devine B; Itzler R; Barrett A; Hawkins N; Lee K; Boersma C; Annemans L; Cappelleri JC
    Value Health; 2011 Jun; 14(4):417-28. PubMed ID: 21669366
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.
    Erder MH; Xie J; Signorovitch JE; Chen KS; Hodgkins P; Lu M; Wu EQ; Sikirica V
    Appl Health Econ Health Policy; 2012 Nov; 10(6):381-95. PubMed ID: 23113551
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comparison of national guidelines for network meta-analysis.
    Laws A; Kendall R; Hawkins N
    Value Health; 2014 Jul; 17(5):642-54. PubMed ID: 25128059
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Indirect comparison of anti-interleukin 17 targeted biological treatments for moderate-to-severe psoriasis.
    Díaz Acedo R; Galvan Banqueri M; Márquez Saavedra E
    J Clin Pharm Ther; 2020 Aug; 45(4):715-721. PubMed ID: 32386269
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
    Reich K; Burden AD; Eaton JN; Hawkins NS
    Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis.
    Taylor RS; Walker S; Ciani O; Warren F; Smart NA; Piepoli M; Davos CH
    Health Technol Assess; 2019 May; 23(25):1-98. PubMed ID: 31140973
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Parametric G-computation for compatible indirect treatment comparisons with limited individual patient data.
    Remiro-Azócar A; Heath A; Baio G
    Res Synth Methods; 2022 Nov; 13(6):716-744. PubMed ID: 35485582
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis.
    Edwards CJ; Sawant R; Garg V; Du EX; Friedman A; Betts KA
    Rheumatol Ther; 2021 Mar; 8(1):167-181. PubMed ID: 33244703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.